IX Biopharma Ltd
SGX:42C
IX Biopharma Ltd
Research & Development
IX Biopharma Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
IX Biopharma Ltd
SGX:42C
|
Research & Development
-S$1.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
Research & Development
-$182.8m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-35%
|
|
|
Haw Par Corporation Ltd
SGX:H02
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hyphens Pharma International Ltd
SGX:1J5
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
IX Biopharma Ltd
Glance View
iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.
See Also
What is IX Biopharma Ltd's Research & Development?
Research & Development
-1.2m
SGD
Based on the financial report for Dec 31, 2025, IX Biopharma Ltd's Research & Development amounts to -1.2m SGD.
What is IX Biopharma Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
14%
Over the last year, the Research & Development growth was 27%. The average annual Research & Development growth rates for IX Biopharma Ltd have been 26% over the past three years , 14% over the past five years .
